Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Drug: Saline placeboBiological: Pembrolizumab/Vibostolimab Co-Formulation
- Registration Number
- NCT05224141
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.
- Detailed Description
With Amendment 4, the experimental Pembrolizumab/Vibostolimab arm (MK-7684A) was discontinued and all ongoing participants were offered an option to move to the comparator Atezolizumab monotherapy arm for the remainder of the study. There will be no further analyses of efficacy, and no European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) and Lung Cancer 13 module (EORTC QLQ-LC13) outcome measures will be reported.
Effective as of Amendment 5, participants with access to approved standard of care (SOC) should be considered for discontinuation from the study. Those benefiting from atezolizumab, but unable to access it as SOC outside the study, may continue on study and receive treatment with atezolizumab until discontinuation criteria are met.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 460
- Has histologically or cytologically confirmed diagnosis of ES-SCLC in need of first-line therapy
- Has ES-SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition or T3-T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan
- Males agree to use contraception, refrain from donating sperm, and abstain from heterosexual intercourse
- Females are not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) or is a WOCBP who uses a highly effective contraceptive method, or is abstinent from heterosexual intercourse
- Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
- Has a predicted life expectancy of >3 months
- Is considered a poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease
- Has received prior treatment for Small Cell Lung Cancer (SCLC)
- Is expected to require any other form of antineoplastic therapy for SCLC while on study
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
- Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has a history of severe hypersensitivity reaction (≥Grade 3) to any study intervention and/or any of its excipients
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has a known history of, or active, neurologic paraneoplastic syndrome
- Has an active infection requiring systemic therapy
- Has a known history of human immunodeficiency virus (HIV) infection
- Has a known history of Hepatitis B or known active Hepatitis C virus infection
- Has had an allogenic tissue/solid organ transplant
- Has had major surgery within prior 3 weeks or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study intervention
- Has symptomatic ascites or pleural effusion
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Atezolizumab Saline placebo Participants will receive 4 cycles (each cycle is 3 weeks) of 1200 mg atezolizumab Q3W, in combination with 100 mg/m\^2 etoposide and platinum (AUC 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of atezolizumab Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Pembrolizumab/Vibostolimab Pembrolizumab/Vibostolimab Co-Formulation Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W), in combination with 100 mg/m\^2 etoposide, and platinum (Area Under the Curve (AUC) 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Pembrolizumab/Vibostolimab Saline placebo Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W), in combination with 100 mg/m\^2 etoposide, and platinum (Area Under the Curve (AUC) 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Pembrolizumab/Vibostolimab Etoposide Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W), in combination with 100 mg/m\^2 etoposide, and platinum (Area Under the Curve (AUC) 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Pembrolizumab/Vibostolimab Cisplatin Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W), in combination with 100 mg/m\^2 etoposide, and platinum (Area Under the Curve (AUC) 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Pembrolizumab/Vibostolimab Carboplatin Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W), in combination with 100 mg/m\^2 etoposide, and platinum (Area Under the Curve (AUC) 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Atezolizumab Etoposide Participants will receive 4 cycles (each cycle is 3 weeks) of 1200 mg atezolizumab Q3W, in combination with 100 mg/m\^2 etoposide and platinum (AUC 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of atezolizumab Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Atezolizumab Carboplatin Participants will receive 4 cycles (each cycle is 3 weeks) of 1200 mg atezolizumab Q3W, in combination with 100 mg/m\^2 etoposide and platinum (AUC 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of atezolizumab Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Atezolizumab Cisplatin Participants will receive 4 cycles (each cycle is 3 weeks) of 1200 mg atezolizumab Q3W, in combination with 100 mg/m\^2 etoposide and platinum (AUC 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of atezolizumab Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1. Atezolizumab Atezolizumab Participants will receive 4 cycles (each cycle is 3 weeks) of 1200 mg atezolizumab Q3W, in combination with 100 mg/m\^2 etoposide and platinum (AUC 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of atezolizumab Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Up to approximately 25.6 months Overall Survival (OS) is the time from randomization to the date of death due to any cause.
- Secondary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Up to approximately 25.6 months Progression-Free Survival (PFS) is the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first.
Objective Response Rate (ORR) Up to approximately 25.6 months Objective Response Rate (ORR) is the percentage of participants who have a Complete Response (CR) (disappearance of all target lesions) or a Partial Response (PR) (at least a 30% decrease in the sum of diameters of target lesions).
Duration of Response (DOR) Up to approximately 25.6 months Duration of Response (DOR) is the time from first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), until progressive disease (PD) or death.
Percentage of Participants Who Experienced an Adverse Event (AE) Up to approximately 60 months An AE is any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Percentage of Participants Who Discontinued Study Treatment Due to an AE Up to approximately 60 months An AE is any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Baseline and up to approximately 37 months The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life (QoL) of individuals with cancer. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome.
Change from Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 Baseline and up to approximately 37 months The EORTC QLQ-C30 is a cancer specific health-related QoL questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function.
Change from Baseline in Dyspnea Score (Item 8) on the EORTC QLQ-C30 Baseline and up to approximately 37 months The EORTC QLQ-C30 is a cancer specific health-related QoL questionnaire. Participant response to the question "Were you short of breath?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea.
Change from Baseline in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) Baseline and up to approximately 37 months The EORTC QLQ-LC13 is a lung cancer specific health-related QoL questionnaire. Participant response to the question "Have you coughed?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing.
Change from Baseline in Chest Pain Score (Item 40) on the EORTC QLQ-LC13 Baseline and up to approximately 37 months EORTC QLQ-LC13 is a lung cancer specific health-related QoL questionnaire. Participant response to the question "Have you had pain in your chest?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain.
Time to True Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the EORTC QLQ-C30 Baseline and up to approximately 37 months The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of individuals with cancer. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.
TTD in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 Baseline and up to approximately 37 months The EORTC QLQ-C30 is a cancer specific health-related QoL questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.
TTD in Dyspnea Score (Item 8) on the EORTC QLQ-C30 Baseline and up to approximately 37 months The EORTC QLQ-C30 is a cancer specific health-related QoL questionnaire. Participant response to the question "Were you short of breath?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.
TTD in Cough Score (Item 31) on the EORTC QLQ-LC13 Baseline and up to approximately 37 months The EORTC QLQ-LC13 is a lung cancer specific health-related QoL questionnaire. Participant response to the question "Have you coughed?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.
TTD in Chest Pain Score (Item 40) on the EORTC QLQ-LC13 Baseline and up to approximately 37 months The EORTC QLQ-LC13 is a lung cancer specific health-related QoL questionnaire. Participant response to the question "Have you had pain in your chest?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.
Trial Locations
- Locations (140)
National Cancer Center Hospital East ( Site 3002)
🇯🇵Kashiwa, Chiba, Japan
Lakeridge Health ( Site 0102)
🇨🇦Oshawa, Ontario, Canada
LungenClinic Grosshansdorf-Onkologie ( Site 0903)
🇩🇪Grosshansdorf, Schleswig-Holstein, Germany
Turku University Hospital-The Department of Pulmonary Medicine ( Site 0701)
🇫🇮Turku, Varsinais-Suomi, Finland
St. James's Hospital ( Site 1200)
🇮🇪Dublin, Ireland
Sheba Medical Center-ONCOLOGY ( Site 1302)
🇮🇱Ramat Gan, Israel
Rambam Health Care Campus-Oncology ( Site 1301)
🇮🇱Haifa, Israel
Shizuoka Cancer Center ( Site 3007)
🇯🇵Nagaizumi, Shizuoka, Japan
Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014)
🇺🇸Boca Raton, Florida, United States
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0200)
🇦🇷Buenos Aires, Caba, Argentina
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0005)
🇺🇸Lancaster, Pennsylvania, United States
Los Angeles Hematology Oncology Medical Group ( Site 0006)
🇺🇸Los Angeles, California, United States
VA West Los Angeles Medical Center ( Site 0004)
🇺🇸Los Angeles, California, United States
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201)
🇦🇷Mar del Plata, Buenos Aires, Argentina
Dana-Farber Cancer Institute ( Site 0018)
🇺🇸Boston, Massachusetts, United States
Anhui Cancer Hospital ( Site 2915)
🇨🇳Hefei, Anhui, China
Fujian Provincial Cancer Hospital-oncology department ( Site 2904)
🇨🇳Fuzhou, Fujian, China
Jilin Cancer Hospital-GCP office ( Site 2909)
🇨🇳Changchun, Jilin, China
The First Hospital of Jilin University ( Site 2914)
🇨🇳Changchun, Jilin, China
Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 0805)
🇫🇷Marseille, Bouches-du-Rhone, France
Shanghai Chest Hospital-Oncology department ( Site 2900)
🇨🇳Shanghai, Shanghai, China
SRH Wald-Klinikum Gera-Lungenkrebszentrum ( Site 0900)
🇩🇪Gera, Thuringen, Germany
Calvary Mater Newcastle ( Site 2703)
🇦🇺Waratah, New South Wales, Australia
Sir Run Run Shaw Hospital-Medical Oncology ( Site 2906)
🇨🇳Hangzhou, Zhejiang, China
Hunan Cancer Hospital ( Site 2907)
🇨🇳Changsha, Hunan, China
West China Hospital Sichuan University ( Site 2903)
🇨🇳Chengdu, Sichuan, China
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1403)
🇮🇹Rozzano, Milano, Italy
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2901)
🇨🇳Beijing, Beijing, China
Henan Cancer Hospital ( Site 2916)
🇨🇳Zhengzhou, Henan, China
The First Affiliated Hospital of Soochow University ( Site 2913)
🇨🇳Suzhou, Jiangsu, China
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 2912)
🇨🇳Wuhan, Hubei, China
Thoraxklinik-Heidelberg gGmbH-Studienzentrum Thoraxonkologie ( Site 0905)
🇩🇪Heidelberg, Baden-Wurttemberg, Germany
Hubei Cancer Hospital ( Site 2922)
🇨🇳Wuhan, Hubei, China
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 2910)
🇨🇳Xi'an, Shaanxi, China
Vaasan Keskussairaala-Department of Clinical Oncology ( Site 0700)
🇫🇮Vaasa, Pohjanmaa, Finland
Zhejiang Cancer Hospital-Oncology ( Site 2919)
🇨🇳Hangzhou, Zhejiang, China
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuyt-Unité d'oncologie thoracique et cutané
🇫🇷Limoges, Haute-Vienne, France
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1401)
🇮🇹Milan, Lombardia, Italy
Torokbalint Tudogyogyintezet-Onkopulmonologiai Jarobeteg Centrum ( Site 1101)
🇭🇺Törökbálint, Pest, Hungary
Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1402)
🇮🇹Naples, Campania, Italy
Kanagawa cancer center-Department of Thoracic Oncology ( Site 3004)
🇯🇵Yokohama, Kanagawa, Japan
Niigata Cancer Center Hospital ( Site 3005)
🇯🇵Niigata-shi, Niigata, Japan
Chonnam National University Hwasun Hospital-Pulmonology ( Site 2800)
🇰🇷Hwasun, Jeonranamdo, Korea, Republic of
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2401)
🇹🇷Istanbul, Turkey
Ege University Medicine of Faculty-Chest Diseases Department ( Site 2402)
🇹🇷Bornova, Izmir, Turkey
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2100)
🇪🇸Barcelona, Spain
I.E.U. Medical Point Hastanesi-Oncology ( Site 2408)
🇹🇷Izmir, Karsiyaka, Izmir, Turkey
Hacettepe Universitesi-oncology hospital ( Site 2409)
🇹🇷Ankara, Turkey
Ankara Bilkent City Hospital ( Site 2403)
🇹🇷Ankara, Turkey
The Christie-Clinical Research Facility ( Site 2607)
🇬🇧Manchester, England, United Kingdom
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2103)
🇪🇸Sevilla, Spain
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2407)
🇹🇷Adana, Turkey
Memorial Ankara Hastanesi-Medical Oncology ( Site 2406)
🇹🇷Ankara, Turkey
Mount Vernon Hospital ( Site 2602)
🇬🇧Northwood, Hillingdon, United Kingdom
Heartlands Hospital-Oncology Research ( Site 2604)
🇬🇧Birmingham, United Kingdom
Infirmary Cancer Care ( Site 0022)
🇺🇸Mobile, Alabama, United States
Kyungpook National University Chilgok Hospital-Pulmonology ( Site 2801)
🇰🇷Deagu, Taegu-Kwangyokshi, Korea, Republic of
Chungnam national university hospital-Department of Internal Medicine ( Site 2802)
🇰🇷Daejeon, Taejon-Kwangyokshi, Korea, Republic of
Fort Wayne Medical Oncology and Hematology ( Site 0013)
🇺🇸Fort Wayne, Indiana, United States
Cancer and Hematology Centers of Western Michigan ( Site 0001)
🇺🇸Grand Rapids, Michigan, United States
Blue Ridge Cancer Care ( Site 0015)
🇺🇸Blacksburg, Virginia, United States
University of Virginia Cancer Center ( Site 0019)
🇺🇸Charlottesville, Virginia, United States
Harbin Medical University Cancer Hospital-oncology of department ( Site 2920)
🇨🇳Harbin, Heilongjiang, China
Sichuan Cancer hospital ( Site 2923)
🇨🇳Chengdu, Sichuan, China
Klinik Penzing-2. Lungenabteilung ( Site 0502)
🇦🇹Vienna, Wien, Austria
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0106)
🇨🇦Kingston, Ontario, Canada
Lungenfachklinik Immenhausen-Thoracic Oncology ( Site 0907)
🇩🇪Immenhausen, Hessen, Germany
Medizinische Hochschule Hannover-Department of Pneumology ( Site 0901)
🇩🇪Hannover, Niedersachsen, Germany
Fudan University Shanghai Cancer Center ( Site 2908)
🇨🇳Shanghai, Shanghai, China
Beaumont Hospital, Dublin-Cancer Clinical Trials & Research Unit ( Site 1201)
🇮🇪Dublin, Ireland
Petz Aladar Egyetemi Oktato Korhaz-Pulmonológia (Dr. Szalai Zsuzsanna) ( Site 1102)
🇭🇺Gyor, Gyor-Moson-Sopron, Hungary
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1400)
🇮🇹Rome, Roma, Italy
Shaare Zedek Medical Center-Oncology ( Site 1300)
🇮🇱Jerusalem, Israel
Korea University Guro Hospital-Internal Medicine ( Site 2803)
🇰🇷Seoul, Korea, Republic of
Maastricht UMC+-Pulmonary disease ( Site 1602)
🇳🇱Maastricht, Limburg, Netherlands
Jeroen Bosch Hospital-Pulmonology ( Site 1605)
🇳🇱Den Bosch, Noord-Brabant, Netherlands
Przychodnia Lekarska KOMED ( Site 1701)
🇵🇱Konin, Wielkopolskie, Poland
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 2102)
🇪🇸Madrid, Madrid, Comunidad De, Spain
H.R.U Málaga - Hospital General-Oncology ( Site 2104)
🇪🇸Málaga, Malaga, Spain
Medipol University Medical Faculty-oncology ( Site 2400)
🇹🇷Istanbul, Turkey
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 2701)
🇦🇺St Albans, Victoria, Australia
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0505)
🇦🇹Linz, Oberosterreich, Austria
Sanatorio Parque ( Site 0202)
🇦🇷Rosario, Santa Fe, Argentina
Isala, locatie Zwolle-Poli Longziekten ( Site 1612)
🇳🇱Zwolle, Overijssel, Netherlands
Medizinische Universität Graz ( Site 0504)
🇦🇹Graz, Steiermark, Austria
CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 0800)
🇫🇷Toulouse, Haute-Garonne, France
University General Hospital of Heraklion ( Site 1004)
🇬🇷Heraklion, Irakleio, Greece
European Interbalkan Medical Center ( Site 1000)
🇬🇷Thessaloniki, Greece
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1105)
🇭🇺Kecskemét, Bacs-Kiskun, Hungary
Aichi Cancer Center Hospital ( Site 3016)
🇯🇵Nagoya, Aichi, Japan
National Hospital Organization Hokkaido Cancer Center ( Site 3015)
🇯🇵Sapporo, Hokkaido, Japan
Kanazawa University Hospital ( Site 3006)
🇯🇵Kanazawa, Ishikawa, Japan
Kansai Medical University Hospital ( Site 3009)
🇯🇵Hirakata, Osaka, Japan
Japanese Foundation for Cancer Research ( Site 3003)
🇯🇵Koto, Tokyo, Japan
National Hospital Organization Kyushu Medical Center ( Site 3013)
🇯🇵Fukuoka, Japan
Okayama University Hospital ( Site 3011)
🇯🇵Okayama, Japan
Hattiesburg Clinic Hematology/Oncology ( Site 0003)
🇺🇸Hattiesburg, Mississippi, United States
Frankston Hospital-Oncology and Haematology ( Site 2702)
🇦🇺Frankston, Victoria, Australia
Ziekenhuis Rijnstate ( Site 1606)
🇳🇱Arnhem, Gelderland, Netherlands
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0203)
🇦🇷ABB, Caba, Argentina
Kepler Universitätsklinikum ( Site 0507)
🇦🇹Linz, Oberosterreich, Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0501)
🇦🇹Wien, Austria
Oulun yliopistollinen sairaala-Oncology and Hematology ( Site 0702)
🇫🇮Oulu, Pohjois-Pohjanmaa, Finland
Errikos Dunant Hospital Center-Second Department of Oncology and Clinical Trials Unit ( Site 1002)
🇬🇷Athens, Attiki, Greece
Sotiria Thoracic Diseases Hospital of Athens ( Site 1003)
🇬🇷Athens, Attiki, Greece
Metropolitan Hospital ( Site 1001)
🇬🇷Athens, Attiki, Greece
Somogy Megyei Kaposi Mór Oktató Kórház-Pulmonologiai Osztaly ( Site 1104)
🇭🇺Kaposvár, Somogy, Hungary
National Hospital Organization Shikoku Cancer Center ( Site 3012)
🇯🇵Matsuyama, Ehime, Japan
Kurume University Hospital ( Site 3014)
🇯🇵Kurume, Fukuoka, Japan
Klaipeda University Hospital-Oncology chemotherapy ( Site 1502)
🇱🇹Klaipeda, Klaipedos Miestas, Lithuania
National Cancer Institute-Department of Thoracic Surgery and Oncology ( Site 1501)
🇱🇹Vilnius, Vilniaus Miestas, Lithuania
Centro de Investigacion Clinica de Oaxaca ( Site 0410)
🇲🇽Oaxaca, Mexico
Medische Centrum Leeuwarden ( Site 1619)
🇳🇱Leeuwarden, Fryslan, Netherlands
Sendai Kousei Hospital ( Site 3001)
🇯🇵Sendai, Miyagi, Japan
Arké SMO S.A. de C.V. ( Site 0401)
🇲🇽Mexico, Distrito Federal, Mexico
Erasmus Medisch Centrum ( Site 1621)
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Martini Ziekenhuis ( Site 1618)
🇳🇱Groningen, Netherlands
Hospital of Lithuanian University of Health Sciences Kauno klinikos-Pulmonology ( Site 1500)
🇱🇹Kaunas, Lithuania
iCan Oncology Center Centro Medico AVE ( Site 0406)
🇲🇽Monterrey, Nuevo Leon, Mexico
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1709)
🇵🇱Siedlce, Mazowieckie, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
🇵🇱Warszawa, Mazowieckie, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1703)
🇵🇱Przemysl, Podkarpackie, Poland
Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 1706)
🇵🇱Prabuty, Pomorskie, Poland
Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1707)
🇵🇱Bystra, Slaskie, Poland
Hospital Civil Fray Antonio Alcalde-Oncology ( Site 0407)
🇲🇽Guadalajara, Jalisco, Mexico
Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 0403)
🇲🇽Guadalajara, Jalisco, Mexico
Med-Polonia Sp. z o. o. ( Site 1710)
🇵🇱Poznan, Wielkopolskie, Poland
Champalimaud Foundation ( Site 1812)
🇵🇹Lisbon, Lisboa, Portugal
Hospital CUF Descobertas ( Site 1815)
🇵🇹Lisbon, Lisboa, Portugal
Centro Hospitalar do Porto - Hospital de Santo António ( Site 1813)
🇵🇹Porto, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 1810)
🇵🇹Porto, Portugal
MedEuropa Bucuresti - Centru de Radioterapie-Oncology ( Site 1905)
🇷🇴București, Bucuresti, Romania
Centrul medical Focus ( Site 1903)
🇷🇴București, Bucuresti, Romania
Cardiomed SRL Cluj-Napoca ( Site 1900)
🇷🇴Cluj-Napoca, Cluj, Romania
Centrul de Oncologie Oncolab-Medical Oncology ( Site 1904)
🇷🇴Craiova, Dolj, Romania
Centrul de Oncologie "Sfântul Nectarie"-Medical Oncology ( Site 1901)
🇷🇴Craiova, Dolj, Romania
Cabinet Medical Oncomed ( Site 1902)
🇷🇴Timișoara, Timis, Romania
Hospital Provincial del Centenario ( Site 0205)
🇦🇷Rosario, Santa Fe, Argentina
Nepean Hospital ( Site 2700)
🇦🇺Penrith, New South Wales, Australia
Beijing Peking Union Medical College Hospital ( Site 2921)
🇨🇳Beijing, Beijing, China